Bullish & Foolish
--
--

Is Veru going out of business?

Loading the full analysis
Reading the filings

VERU INC. (VERU) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

VERU INC. (VERU) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 16/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $45.0M
Last close $2.64
Revenue growth (YoY) -100.0%
Dividend yield 0.0%

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (51.1% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Fragile
8-11 mo of estimated runway from 2026-06-30, based on $23.9M of cash and short-term investments against $30.0M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.
Business quality - Pre-commercial
Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.
Trajectory - Clinical progress unavailable
Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Demanding
15.1% net-cash backing support a demanding pre-commercial Valuation assessment.
Event risk - Critical event risk
Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 4 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

  • Shares dilution YoY: Reverse split detected; adjusted share change (51.1% YoY) and the capital-structure risk is penalized.
  • Debt / Equity: -0.75x (Net Cash)
  • ROIC: -227.35%
  • Filing event risk: Going-Concern Warning (-8 pts)
  • Revenue CAGR (3Y): -100.00%
  • Return on Assets: -61.38%
  • Price / Earnings: Unprofitable (see Valuation)
  • Cash Runway (years): 0.79y

Read from filings through 2026-08-10.

Price as of 2026-09-07.

Headline score detail

Source coverage and limitations
--
Reference Links